Date:5/12/2011

rams (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2010, our Form 10-Q for the three months ended March 3
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Inovio Pharmaceuticals to Present at Investor Conferences
2. Inovio Pharmaceuticals, Transgene and ChronTech Pharma to Collaborate on Heterologous Prime-Boost Therapeutic Vaccination Against Hepatitis C
3. OncoSec Medical Closes Purchase and License Agreement for Tumor Therapy Technology with Inovio Pharmaceuticals
4. Inovio Pharmaceuticals to Present at Scientific Conferences
5. Inovio Pharmaceuticals Receives U.S. DOD Small Business Innovation Research Grant for Multi-Vaccine DNA Delivery Device Development
6. Inovio Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
7. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
8. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
9. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
10. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
11. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference